We are steadily implementing the important measures necessary for achieving the objectives of the mid-term management plan and strive to always engage in conscientious corporate activities and enhance corporate governance.

Seikagaku Corporation aims to enhance its value to society by contributing to the health and well-being of people around the world by applying glycoscience expertise to proprietary technology to create innovative new drugs that patients truly need on a wider, global scale.

 

We have positioned the period of the three-year Mid-term Management Plan instituted in November 2019 as a period for solidifying our profit foundation in order to lay out a path for revived growth and are steadily implementing three important measures: 1) Accelerating new drug discovery to become the pillar of new profits, 2) Solidifying the profit foundation through market expansion of new products, and 3) Productivity improvement reforms. 

 

In the fiscal year ended March 31, 2021, we obtained manufacturing and marketing approval in Japan for the joint function improvement agent JOYCLU that we launched in May through sales partner Ono Pharmaceutical Co, Ltd. JOYCLU is a formulation in which hyaluronic acid and diclofenac (an anti-inflammatory drug) are chemically bound using Seikagaku’s own proprietary technology. It is expected to contribute to improvement of the quality of life of patients as a new treatment option for osteoarthritis (knee joint and hip joint). We will leverage the launch of JOYCLU as an opportunity to steadily implement the important measures necessary for achieving the objectives of the Mid-term Management Plan and strive to always engage in conscientious corporate activities and enhance corporate governance.

 

We look forward to the continuing guidance and support of our shareholders and other stakeholders.

June 2021
 Ken Mizutani
 President & CEO